Revolution Medicines Announces First Patient Dosed in Phase III Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

0
45
Revolution Medicines, Inc. announced that the first patient has been dosed in RASolute 302, a Phase III registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic PDAC.
[Revolution Medicines]
Press Release